Mount Vernon Cancer Centre (MVCC) has been named the highest international participant recruiter for The CABOPOINT Study; a phase 2 clinical trial evaluating the efficacy and safety of a targeted therapy drug called Cabozantinib as a second line treatment for advanced renal cell cancer (RCC).
RCC is a type of kidney cancer that starts in the lining of very small tubes in the kidney. Like other cancers, RCC begins as a small growth and grows larger over time. The study looks at patient responses to treatment, quality of life and safety of the treatment and includes patients who had cancer which had already progressed when they were taking either Ipilimumab/Nivolumab (immunotherapy treatments) or were undergoing other targeted therapies.
The site recruited a total of 9 patients with RCC which had spread to other parts of the body, had not responded adequately to first line treatments, and could not be surgically removed.
The study is led locally by Consultant Medical Oncologist and Principal Investigator Dr Anand Sharma, who remarked on its importance:
“This trial will answer an important question of the best treatment option in second line advanced renal cancer, and is looking at the suitable treatment algorithm, after patients fail on first line immunotherapy combination treatments.”
Internationally, the study recruited patients across 50 centres with MVCC being the highest recruiter of all participating sites.
Dr Sharma also commented on the site and renal research team’s achievements and the overall impact for patients:
“Mount Vernon Cancer Centre is amongst the top 5 highest recruiters for renal cancer trials in the country. Our centre offers novel therapies to patients, as soon as they are approved by the regulatory authorities or as part of clinical trials.”
Recruitment to the clinical trial has now completed and patients will be followed up locally by the renal research team so that the study can continue to assess the safety of the treatment, patient response and overall quality of life. A summary of the trial results will be made publicly available by the trial sponsor at the end of the study.